S

Surgical Science Sweden AB
STO:SUS

Watchlist Manager
Surgical Science Sweden AB
STO:SUS
Watchlist
Price: 125 SEK -1.26%
Market Cap: 6.4B SEK

Intrinsic Value

The intrinsic value of one SUS stock under the Base Case scenario is 183.23 SEK. Compared to the current market price of 125 SEK, Surgical Science Sweden AB is Undervalued by 32%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

SUS Intrinsic Value
183.23 SEK
Undervaluation 32%
Intrinsic Value
Price
S
Worst Case
Base Case
Best Case

Valuation History
Surgical Science Sweden AB

SUS
Valuation History
HIDDEN
Show
Valuation History Unavailable

Historical valuation for SUS cannot be conducted due to limitations such as insufficient data or other constraints.

Valuation In Progress...
Valuation In Progress...
0%

Fundamental Analysis

Surgical Science Sweden AB
STO:SUS
SE
Health Care
Market Cap
6.4B SEK
IPO
Jun 19, 2017
SE
Health Care
Market Cap
6.4B SEK
IPO
Jun 19, 2017
Price
krfalse
EPS
krfalse
Company Overview
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about SUS?
Bearish
Neutral
Bullish
AI Assistant
AI Assistant
Ask me anything about Surgical Science Sweden AB
Financials
Annual
Quarterly
TTM

Balance Sheet Decomposition
Surgical Science Sweden AB

Current Assets 1.4B
Cash & Short-Term Investments 968.2m
Receivables 180.4m
Other Current Assets 277.5m
Non-Current Assets 4.1B
Long-Term Investments 8m
PP&E 101.5m
Intangibles 3.9B
Other Non-Current Assets 16.3m
Efficiency

Free Cash Flow Analysis
Surgical Science Sweden AB

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Surgical Science Sweden AB

Revenue
884.1m SEK
Cost of Revenue
-286.2m SEK
Gross Profit
597.9m SEK
Operating Expenses
-453.6m SEK
Operating Income
144.3m SEK
Other Expenses
-12.7m SEK
Net Income
131.6m SEK
Fundamental Scores

SUS Profitability Score
Profitability Due Diligence

Surgical Science Sweden AB's profitability score is 58/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Exceptional 3-Years Revenue Growth
Positive Free Cash Flow
Exceptional Revenue Growth Forecast
58/100
Profitability
Score

Surgical Science Sweden AB's profitability score is 58/100. The higher the profitability score, the more profitable the company is.

SUS Solvency Score
Solvency Due Diligence

Surgical Science Sweden AB's solvency score is 87/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Negative Net Debt
87/100
Solvency
Score

Surgical Science Sweden AB's solvency score is 87/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

SUS Price Targets Summary
Surgical Science Sweden AB

Wall Street analysts forecast SUS stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for SUS is 198.49 SEK with a low forecast of 181.8 SEK and a high forecast of 225.75 SEK.

Lowest
Price Target
181.8 SEK
45% Upside
Average
Price Target
198.49 SEK
59% Upside
Highest
Price Target
225.75 SEK
81% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for SUS is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

SUS Insider Trading
Buy and sell transactions by insiders

What is the Intrinsic Value of one SUS stock?

The intrinsic value of one SUS stock under the Base Case scenario is 183.23 SEK.

Is SUS stock undervalued or overvalued?

Compared to the current market price of 125 SEK, Surgical Science Sweden AB is Undervalued by 32%.

Back to Top